“We are disappointed with this outcome. The treatment of Alzheimer’s disease psychosis continues to be an area of high unmet need, for which there is no approved therapy,” said company CEO Steve Davis.
https://www.pharmalive.com/wp-content/uploads/2022/06/ReutersFDA6-10-2022.jpg8001200Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-08-05 00:46:012022-08-05 10:41:34U.S. FDA declines to approve expanded use of Acadia’s antipsychotic drug